Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Atlantic Healthcare granted U.S. patent extending IP cover of alicaforsen in the treatment of inflammatory bowel disease

Atlantic Healthcare
Posted on: 08 Nov 16

Patent covers use of antisense oligonucleotides to treat rectal stump inflammation and pain


Cambridge, UK, and Raleigh, NC 7 November 2016. Atlantic Healthcare plc, an emerging trans-Atlantic pharmaceutical company with a core focus on gastrointestinal (GI) disorders, announces that the U.S. Patent and Trademark Office has granted U.S. Patent No. 9453221.


The Group's product, alicaforsen, is targeting the treatment of inflammatory bowel disease (IBD) and its most advanced programme is undergoing Phase 3 clinical development for the treatment of IBD pouchitis. With the Group's strategy to broaden the indications and formulations based on alicaforsen, the granted patent extends the use of alicaforsen in IBD-related rectal stump inflammation and pain.


In the treatment of IBD, a rectal stump is formed through a surgical procedure in order to rest a diseased colon, as an alternative to total colectomy. Patients with a rectal stump can experience inflammation, pain, and discharge for which there is no approved therapy. They can also experience a significant reduction in quality of life.


Toby Wilson Waterworth, CEO at Atlantic Healthcare said: “This latest granted patent extends the family of intellectual property protection covering Atlantic Healthcare's product, alicaforsen, for the treatment of multiple indications within inflammatory bowel disease (IBD). The IP protection, which includes the use of alicaforsen in ulcerative colitis and pouchitis, provides protection for alicaforsen out to 2030 and beyond.


As with other forms of IBD, existing therapies to treat pain and inflammation in a rectal stump have limited efficacy, with patients often becoming resistant to treatment. With no approved therapy there is a clear unmet clinical need, which alicaforsen has the potential to address as a first in class drug, harnessing an alternative mode of action.” 



For more information please contact:


Atlantic Healthcare

Toby Wilson Waterworth (CEO)

+44 1799 512 055


Adam Michael (Head of Communications)

+44 1799 512 055

+44 777 588 1813


Consilium Strategic Communications

Mary-Jane Elliott / Matthew Neal / Jessica Hodgson / Melissa Gardiner

+44 20 3709 5700

Editor's Details

Mike Wood

Last updated on: 08/11/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.